Rhabdomyosarcoma is the third most prevalent children’s cancer and approximately 3% of children’s cancers are rhabdomyosarcomas with 250 US and 60 UK children diagnosed a year.
A recent paper has identified several phenothiazinyl chalcones which are cytotoxic to rhabdomyosarcoma cells. Previous work has shown that modifications to the double bond of chalcones can markedly improve (20x) the cytotoxic action of chalcones to cancer cell lines.
This project aims to similarly modify the phenothiazinyl derived chalcones and identify a suitable candidate for pre-clinical evaluation as an agent to combat rhabdomyosarcoma.
Grant Award – Studentship 2018-2019
Funding Award – £1000
Funding Awarded to – Dr John Hadfield
Research Location – University of Salford
Lead Researcher – Dr John Hadfield
0161 295 3864 